Diagnoptics News

What's new?

Read all news items about the AGE Reader, Diab-spot and DiagnOptics.

DiagnOptics and PATH partner on project on diabetes screening in India

Groningen, the Netherlands – February 6, 2012
DiagnOptics and PATH partner on a clinical study in which the performance of point-of-care technologies for diabetes screenings will be tested in India. DiagnOptics’ recently launched Diab-spot will be tested and further developed in this clinical study in India.

There is a strong need to evaluate point-of-care (POC) technologies for diabetes screening in Indian settings and compare their performance with existing technologies. Through this study, the investigators will explore whether a testing model can guide disease treatment and management without the routine use of laboratory measurements. This study focuses on technologies that measure advanced glycation endproducts (AGEs) (such as the AGE Reader and Diab-spot) and glycemic control by POC glycated hemoglobin (HbA1c) readers.

Diab-spot offers a noninvasive and convenient method for diabetes screening with an immediate screening result on the spot. “DiagnOptics is convinced that Diab-spot can make a difference in the mission to find undiagnosed diabetics,” says DiagnOptics managing director, Bart van den Berg.

The principal investigator of this research project is Dr. Bernhard H. Weigl from the United States collaborator, PATH.  The study is funded under PATH’s Center for POC Diagnostics for Global Health, which is supported by National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering (NIBIB). The Indian principal investigator is Dr. V.Mohan from the Madras Diabetes Research Foundation (MDRF) Chennai, India. PATH and MDRF hope that results from this study will provide the basis for larger programmatic activities to use and benefit from the novel low-cost technical approaches in the areas of diabetes screening and control in India.

Share this link on:

Latest news items

More Information
Request information

Would you like to learn more about our products? Request any information you wish to receive here.

AGE Reader mu
Non-invasive cardiovascular risk assessment
Age Reader MU
The AGE Reader mu is the next generation AGE Reader that combines a high measurement quality standard with an innovative design, at a reduced pricelevel. The AGE Reader mu is a perfect tool for diabetologists and family doctors. Read more »
Newsletter subscription

If you want to receive the newsletter with information about DiagnOptics' products, please send us your email address.

About the company

More information about Diagnoptics.

Information for patients

Information on Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.